FDA advisory panels show high rates of undisclosed pharma ties for patient reps
A new analysis reveals that nearly 40 percent of FDA advisory committee meetings over the last two decades included patient or consumer representatives with active ties to pharmaceutical-funded advocacy groups.
Undisclosed financial connections found
More than one in ten meetings featured a representative linked to an organization receiving money from the drugmaker reviewing the medicine. Most of these organizational links were not disclosed during the proceedings, which raises questions about potential influence on voting behavior.
Committee composition varies widely
For several specific committees, the number of such representatives exceeded 50 percent of the total membership. The study noted that conflict-of-interest policies exist for scientific members but remain underdeveloped regarding industry funding of patient groups.
Policies lack clarity on ties
The analysis was published in Health Affairs Scholar and highlights gaps in current regulations concerning these specific representatives. Researchers point out that existing rules do not adequately address funding sources for advocacy groups whose members appear on committees.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.